Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

March 2, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…
Press Releases
February 17, 2023: MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders
Press Releases
February 6, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
February 3, 2023: MaaT Pharma Receives U.S. FDA Response Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022
Press Releases
January 27, 2023: MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux

See more

Media Coverage

Media

February 23, 2023: Les Echos Investir – Maat Pharma : l’approche novatrice du microbiote (French only)

https://investir.lesechos.fr/conseils-boursiers/conseils-actions/maat-pharma-lapproche-novatrice-du-microbiote-1909546
Media
February 22, 2023: Microbiome Post – Interview of Hervé Affagard
Media
December 13, 2022: BSmart interview of Hervé Affagard – Smart Tech (French only)
Media
December 13, 2022: BFM Business interview of Hervé Affagard – Good Morning Business
Media
MedNous – FDA approves first faecal microbiota product
Media
Labiotech – FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

See more

Posters

Posters

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Posters
Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program
Posters
Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
Posters
Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes
Posters
EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics
Posters
ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

Videos

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma